Effective joint regeneration using regenerating treatments and surgery

Cellular Matrix

Cellular Matrix is an innovative combination of platelet rich plasma and hyaluronic acid in a single-step closed system.

It shows synergistic effect alleviating pain and reducing inflammation. Hyaluronic acid improves properties of synovial fluid and prolongs longevity of growth factors contained in blood platelets. Platelet rich plasma stimulates articular cartilage repair. The main goal of combined use of PRP and hyaluronic acid is to modify the microenvironment of the joint through modifying inflammatory signals and cell growth. It is achieved owing to the chemical compounds which complementarily enable effective treatment.

A single intraarticular injection of PRP and hyaluronic acid decreases pain and inflammation, improving mechanical joint function. Hyaluronic acid acts as a scaffolding to transport and protect biological compounds contained in blood platelets. The formulation is indicated for symptomatic treatment of degenerative joint disease to decrease pain and improve joint mobility.

Patient eligibility assessment

Patient eligibility assessment for CellularMatrix treatment involves a consultation with an orthopaedist and is based on patient medical history, clinical examination findings as well as an additional ultrasound scan and x-rays.

The procedure encompasses the following stages:

The treatment is prepared as a single step, in a sterile closed system, using autologous (patient’s own) blood. CellularMatrix treatment involves 1-3 intraarticular injections (i.e. administered to the joint), depending on your medical condition and needs.

  1. Venous blood sample collection.
  2. Placing patient’s blood in a centrifuge for separation.
  3. The obtained platelet rich plasma mixed with hyaluronic acid is administered by the orthopaedist as an ultrasound-guided injection to the target site.

Post-treatment care and recommendations

Avoid sports-related activity for a week following an injection.

Reduce your activity throughout the entire therapy duration.

An intraarticular injection (i.e. injection administered to the joint) may cause pain, oedema and/or exudate (fluid accumulation in tissues).  The symptoms usually resolve within about a week.

Joint, tendon, ligament and/or muscle regeneration takes time and its duration depends on your medical condition and symptoms. The effect of such growth factor treatment can be assessed at 3 months following the last injection.

Indications for CellularMatrix Viscosupplementation:

  • Treatment in early stages of degenerative joint disease and joint chondromalacia.
  • Prevention in the elderly to relieve pain and protect the joints.
  • Prevention in physically active individuals or professional athletes to delay ageing, protect articular cartilage and ensure its proper nourishment, decrease load on joints when running or practising other sports such as triathlon.
  • Tendon and ligament overuse injury, such as: tennis elbow, golfer’s elbow, runner’s knee, Achilles tendon overuse injury, calcaneal spur ligament and capsular tears, such as lateral collateral ligament tear, Achilles tendon tear.
  • plantar fasciitis.
  • joint pain.

Contraindications to Cellular Matrix Viscosupplementation:

  • known hypersensitivity to sodium hyaluronate
  • history of autoimmune disease
  • venous or lymphatic stasis
  • infection or severe arthritis
  • skin disease or infection at the injection site
  • pregnancy and breastfeeding
  • active malignancy, currently receiving chemotherapy, radiation therapy or other cancer treatment
  • infections